Publication: How can we do pharmacokinetic studies in the tropics?
Issued Date
2001-01-01
Resource Type
ISSN
00359203
Other identifier(s)
2-s2.0-0035408046
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.95, No.4 (2001), 347-351
Suggested Citation
Julie A. Simpson, Leon Aarons, Nicholas J. White How can we do pharmacokinetic studies in the tropics?. Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.95, No.4 (2001), 347-351. doi:10.1016/S0035-9203(01)90178-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26594
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
How can we do pharmacokinetic studies in the tropics?
Author(s)
Abstract
Information regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug provides the basis for optimizing dosing. PK-PD information should be obtained from patients representative of the overall target population, but in many tropical hospitals or health care facilities it may be medically hazardous or logistically difficult for an ill patient or a young child to be sampled repeatedly. Traditional methods used to determine the pharmacokinetic properties of a drug require analysis of a large number of blood samples per subject. However, using modern statistical methods, sparse datasets (i.e. with assay results from only a few, or as little as one blood sample per subject) can now be analysed by a method termed 'the population approach'. Modern assay techniques can often be adapted to small blood volumes allowing finger prick blood samples to be taken. One of the major aims of the population approach is to distinguish and characterize patient and disease contributors to inter-individual variance in drug pharmacokinetics. The purpose of this paper is to explain the basis of the population approach, to highlight its advantages compared to traditional methods of analysis, and to review the application of the population approach to data from field studies of antimalarial drugs. The design of population pharmacokinetic studies is also discussed briefly. The principles discussed in the paper are also applicable to pharmacodynamic data.